Cargando…

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

BACKGROUND: To evaluate the safety of besifloxacin ophthalmic suspension 0.6% when used in laser-assisted in situ keratomileusis (LASIK) prophylactic antibiotic regimens. METHODS: Retrospective surveillance of LASIK surgery cases where besifloxacin ophthalmic suspension 0.6% or moxifloxacin ophthalm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nielsen, Steven A, McDonald, Marguerite B, Majmudar, Parag A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552478/ https://www.ncbi.nlm.nih.gov/pubmed/23355771 http://dx.doi.org/10.2147/OPTH.S38279

Ejemplares similares

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients [Corrigendum]
Publicado: (2013)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau, Joseph M, et al.
Publicado: (2021)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
por: Malhotra, Ranjan, et al.
Publicado: (2012)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%
por: DeCory, Heleen H., et al.
Publicado: (2020)

Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
por: Khimdas, S., et al.
Publicado: (2011)

Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation
por: de Jesus, José Izo Santana da Silva, et al.
Publicado: (2022)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2015)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
por: Haas, Wolfgang, et al.
Publicado: (2013)

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
por: Mah, Francis S., et al.
Publicado: (2016)

Ophthalmic Charts
Publicado: (1892)

Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study
por: Kuna, Piotr, et al.
Publicado: (2023)

Laser-Assisted In Situ Keratomileusis (LASIK) Enhancement for Residual Refractive Error after Primary LASIK
por: Moshirfar, Majid, et al.
Publicado: (2022)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang, Xiao Jing, et al.
Publicado: (2011)

Evaluation of the efficiency and safety of TransPRK and FS-LASIK refractive procedures on patients with astigmatism and amblyopia
por: Sima, George, et al.
Publicado: (2023)

Assessment of refractive outcome of femtosecond-assisted LASIK for hyperopia correction
por: El-Naggar, Mohamed Tarek, et al.
Publicado: (2017)

Predictability and stability of refraction with increasing optical zone diameter in hyperopic LASIK
por: El-Helw, Mostafa A, et al.
Publicado: (2010)

Nano-Formulating Besifloxacin and Employing Quercetin as a Synergizer to Enhance the Potency of Besifloxacin against Pathogenic Bacterial Strains: A Nano-Synergistic Approach
por: Al Hagbani, Turki, et al.
Publicado: (2023)

LASIK for Spherical Refractive Myopia: Effect of Topographic Astigmatism (Ocular Residual Astigmatism, ORA) on Refractive Outcome
por: Frings, Andreas, et al.
Publicado: (2015)

Under-the-Flap Crosslinking and LASIK in Early Ectasia with Hyperopic Refractive Error
por: el-Khoury, Sylvain, et al.
Publicado: (2018)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
por: Comstock, Timothy L, et al.
Publicado: (2010)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Hyperopic refractive correction by LASIK, SMILE or lenticule reimplantation in a non-human primate model
por: Williams, Geraint P., et al.
Publicado: (2018)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Role of percent peripheral tissue ablated on refractive outcomes following hyperopic LASIK
por: Fatseas, George, et al.
Publicado: (2017)

One year refractive outcomes of Femtosecond-LASIK in mild, moderate and high myopia
por: Tabacaru, Bogdana, et al.
Publicado: (2017)

Relative peripheral refraction across 4 meridians after orthokeratology and LASIK surgery
por: Queirós, António, et al.
Publicado: (2018)

Comment on “Under-the-Flap Crosslinking and LASIK in Early Ectasia with Hyperopic Refractive Error”
por: Wallerstein, Avi, et al.
Publicado: (2019)

Corrigendum to “Under-the-Flap Crosslinking and LASIK in Early Ectasia with Hyperopic Refractive Error”
por: el-Khoury, Sylvain, et al.
Publicado: (2019)

Quality of vision after myopic refractive surgeries: SMILE, FS-LASIK, and ICL
por: Du, Huiyi, et al.
Publicado: (2023)

Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex
por: Kato, C. O. Sayaka, et al.
Publicado: (2018)

Effect of storage temperature on the dispersibility of commercially available 0.1% fluorometholone ophthalmic suspension
por: Obata, Tokio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dq045eqeql9l0lter15aa2rne1